Declopramide

Declopramide (3-Chloroprocainamide) is an orally active antitumor agent, which inhibits proliferation of cancer cells HL60 and K562, and inhibits tumor growth of human brain astrocytoma (T24) in mouse model. Declopramide induces apoptosis, inhibits NF-κB through inhibition of IκBα degradation. Declopramide serves also as chemosensitizer in research[1][2][3].

Product Specifications

CAS Number

[891-60-1]

Product Name Alternative

3-Chloroprocainamide

UNSPSC

12352005

Hazard Statement

H302

Target

Apoptosis; NF-κB

Type

Reference compound

Related Pathways

Apoptosis; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/declopramide.html

Smiles

O=C(NCCN(CC)CC)C1=CC=C(N)C(Cl)=C1

Molecular Formula

C13H20ClN3O

Molecular Weight

269.77

Precautions

P264-P270-P330-P501

References & Citations

[1]Hua J, et al., Comparison of antitumor activity of declopramide (3-chloroprocainamide) and N-acetyl-declopramide. Anticancer Res. 1999 Jan-Feb;19 (1A) :285-90. |[2]Hua J, et al., Pharmacokinetics and central nervous system toxicity of declopramide (3-chloroprocainamide) in rats and mice. Anticancer Drugs. 1999 Jan;10 (1) :79-88. |[3]Lindgren H, et al., Differential usage of IkappaBalpha and IkappaBbeta in regulation of apoptosis versus gene expression. Biochem Biophys Res Commun. 2003 Jan 31;301 (1) :204-11.